Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133136 | 1.00 | TP53 (0.50) | TP53AAK1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL7718349 | 1.00 | TP53 (0.50) | TP53AAK1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL30752785 | 0.88 | MAPT (0.41) | TP53AAK1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL5583501 | 0.85 | TP53 (0.56) | TP53ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL29042821 | 0.84 | AAK1 (0.49) | TP53AAK1CTSSCTSKCTSB | |
| SCHEMBL29042833 | 0.84 | AAK1 (0.49) | TP53AAK1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL30374901 | 0.84 | AAK1 (0.49) | TP53AAK1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL19585926 | 0.83 | AAK1 (0.52) | AAK1ALDH1A1CTSSCTSKGAA | |
| SCHEMBL19585925 | 0.83 | AAK1 (0.52) | AAK1ALDH1A1CTSSCTSKGAA | |
| SCHEMBL8272439 | 0.83 | LMNA (0.54) | TP53AAK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | TP53 4589/4885AAK1 2208/4885ALDH1A1 779/4885 |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | TP53 4883/4885AAK1 1841/4885ALDH1A1 141/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | TP53 4527/4885AAK1 2872/4885ALDH1A1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.